BR112015027388A2 - Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica - Google Patents

Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica

Info

Publication number
BR112015027388A2
BR112015027388A2 BR112015027388A BR112015027388A BR112015027388A2 BR 112015027388 A2 BR112015027388 A2 BR 112015027388A2 BR 112015027388 A BR112015027388 A BR 112015027388A BR 112015027388 A BR112015027388 A BR 112015027388A BR 112015027388 A2 BR112015027388 A2 BR 112015027388A2
Authority
BR
Brazil
Prior art keywords
cxcr5
polynuclotides
pharmaceutical composition
host cell
production method
Prior art date
Application number
BR112015027388A
Other languages
English (en)
Inventor
Leger Olivier
Bradfield Paul
Power Christine
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BR112015027388A2 publication Critical patent/BR112015027388A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ANTICORPO MONOCLONAL OU PORÇÃO DO MESMO QUE SE LIGA A CXCR5, SEU MÉTODO DE PRODUÇÃO E SEU USO, POLINUCLEOTÍDEOS, VETORES DE EXPRESSÃO, CÉLULA HOSPEDEIRA, E COMPOSIÇÃO FARMACÊUTICA. A invenção refere-se a anticorpos monoclonais contra CXCR5 humano e a seu uso no tratamento de doenças autoimunes ou inflamatórias, bem como cânceres.
BR112015027388A 2013-05-02 2014-04-30 Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica BR112015027388A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166251 2013-05-02
PCT/EP2014/058903 WO2014177652A1 (en) 2013-05-02 2014-04-30 Monoclonal antibody directed against cxcr5

Publications (1)

Publication Number Publication Date
BR112015027388A2 true BR112015027388A2 (pt) 2017-08-29

Family

ID=48184103

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027388A BR112015027388A2 (pt) 2013-05-02 2014-04-30 Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica

Country Status (14)

Country Link
US (1) US9534054B2 (pt)
EP (1) EP2992014A1 (pt)
JP (1) JP6522585B2 (pt)
KR (1) KR20160003804A (pt)
CN (1) CN105392802B (pt)
AU (1) AU2014261398B2 (pt)
BR (1) BR112015027388A2 (pt)
CA (1) CA2909587A1 (pt)
HK (1) HK1217340A1 (pt)
MX (1) MX2015015232A (pt)
RU (1) RU2015150723A (pt)
SG (1) SG11201508502RA (pt)
WO (1) WO2014177652A1 (pt)
ZA (1) ZA201508081B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007641A (es) * 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
FR3061716B1 (fr) * 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
EP3717516A1 (en) * 2017-12-01 2020-10-07 Pfizer Inc Anti-cxcr5 antibodies and compositions and uses thereof
BR112020025718A2 (pt) * 2018-06-18 2021-04-06 Bayer Aktiengesellschaft Conjugados de ligante/agente ativo direcionados contra cxcr5, tendo aglutinantes enzimaticamente cliváveis e perfil de atividade melhorado

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
UA117446C2 (uk) * 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use

Also Published As

Publication number Publication date
WO2014177652A1 (en) 2014-11-06
JP6522585B2 (ja) 2019-05-29
US9534054B2 (en) 2017-01-03
CA2909587A1 (en) 2014-11-06
RU2015150723A (ru) 2017-06-07
ZA201508081B (en) 2017-09-27
AU2014261398B2 (en) 2019-08-29
US20160115235A1 (en) 2016-04-28
MX2015015232A (es) 2016-02-22
JP2016524595A (ja) 2016-08-18
CN105392802B (zh) 2019-09-03
EP2992014A1 (en) 2016-03-09
KR20160003804A (ko) 2016-01-11
AU2014261398A1 (en) 2015-11-12
CN105392802A (zh) 2016-03-09
HK1217340A1 (zh) 2017-01-06
SG11201508502RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
UY35044A (es) ANTICUERPOS ANTI-dDr1
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
AR103867A1 (es) Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
EA201591801A1 (ru) Лекарственные конъюгаты антител
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BR112014018630A2 (pt) alvejamento de glicanos de sulfato de condroitina
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201890143A2 (ru) Антитела против pdgfr-бета и их применения
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
BR112018068678A2 (pt) anticorpos anti-mica
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
NZ705109A (en) Antibody formulations and uses thereof
BR112016010513A2 (pt) anticorpos anti-il-17, método de produção e uso dos mesmos
BR112017023131A2 (pt) anticorpos anti- fcrn
PE20160528A1 (es) Anticuerpos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.